BWX Technologies, Inc.

(New York Stock Exchange)
Back to all articles
Very Bullish +85

BWX Technologies Targets $6B Revenue by 2030 as Nuclear Backlog Surges

Capacity expansion Government funding Regulatory approval AI-generated analysis

πŸ“ˆ BWXT raised its long-term targets to $5.5B-$6B revenue by 2030, with adjusted EBITDA of $1.1B-$1.2B and free cash flow of $525M-$575M.

πŸ“Š The company's backlog surged to $8.4 billion, more than doubling from the prior Investor Day and providing nine quarters of work at current run rates.

πŸ’° CEO Rex Geveden expects margins to expand from 17.5% in 2026 to approximately 20% by 2030 as commercial operations scale.

🏭 Commercial Operations is projected to deliver high-teens annual revenue growth through 2030, driven by expanded nuclear component supply.

πŸ›‘οΈ Government Operations accounts for nearly $7 billion of total backlog, with naval propulsion representing about 70% of segment revenue.

πŸ’Ό BWXT announced the sale of a majority interest in BWXT Medical for up to $800 million while retaining a ~20% stake.

πŸ”‹ The company secured major contracts including a $1.63B deal for depleted uranium and a $1.5B contract for centrifuge technology scaling.

βš™οΈ BWXT delivered over 325 commercial steam generators and has 60 more in backlog, expanding its Cambridge, Ontario facility by 40%.

🌍 The company is pursuing opportunities in the U.S., Europe, and Canada, including work on AP1000 deployment in Bulgaria and SMR projects.

πŸš€ Naval nuclear propulsion business is expected to grow at a 4% to 6% compound annual rate based on existing shipbuilding plans.

πŸ”¬ BWXT completed fuel delivery for Project Pele and is preparing the reactor for shipment and fueling at Idaho National Laboratory.

πŸ’Έ CFO Mike Fitzgerald stated the company expects to generate more than $2 billion in cumulative free cash flow from 2026 through 2030.

πŸ“‰ Capital expenditures are planned to remain in a range of 5% to 6% of revenue, with disciplined allocation for growth and maintenance.

🏒 BWXT operates 16 major manufacturing sites across North America and Europe, utilizing 5 million square feet of nuclear-qualified space.

πŸ‘₯ The company employs approximately 11,400 people globally to support its diverse portfolio of government and commercial nuclear solutions.

Bullish Signals
  • BWXT raised its long-term revenue target to $5.5B-$6B by 2030, representing low-double-digit annual growth from the 2026 baseline.
  • The company's backlog more than doubled to $8.4 billion, providing roughly nine quarters of work at the current run rate.
  • Margins are expected to expand from 17.5% in 2026 to approximately 20% by 2030 as commercial operations scale.
  • Commercial Operations is projected to deliver high-teens annual revenue growth through 2030, driven by expanded nuclear component supply.
  • BWXT announced the sale of a majority interest in BWXT Medical for up to $800 million, providing significant capital for organic investment and acquisitions.
  • The company secured major contracts including a $1.63B deal for depleted uranium and a $1.5B contract for centrifuge technology scaling.
  • BWXT delivered over 325 commercial steam generators and has 60 more in backlog, expanding its Cambridge, Ontario facility by 40%.
  • Naval nuclear propulsion business is expected to grow at a 4% to 6% compound annual rate based on existing shipbuilding plans.
  • BWXT expects to generate more than $2 billion in cumulative free cash flow from 2026 through 2030, supporting shareholder returns.
  • The company reaffirmed its 2026 guidance and provided an initial 2027 framework calling for high-single-digit revenue and adjusted EBITDA growth.
Full Analysis
BWX Technologies (NYSE: BWXT) significantly raised its long-term growth outlook at its 2026 Investor Day, targeting total revenue between $5.5 billion and $6 billion by 2030. The company projects adjusted EBITDA of $1.1 billion to $1.2 billion and free cash flow of $525 million to $575 million for the same period, with operating margins expected to expand from 17.5% in 2026 to approximately 20% by 2030. The company's order backlog has more than doubled to $8.4 billion since early 2024, representing roughly nine quarters of work at the current run rate. CEO Rex Geveden highlighted a diversified portfolio spanning commercial nuclear projects, naval propulsion systems, advanced reactors, and special materials contracts, positioning BWXT as a global industrial champion with manufacturing sites across North America and Europe. Growth is driven by high-teens annual revenue growth in Commercial Operations through 2030 and strong performance in Government Operations. Key drivers include the sale of a majority interest in BWXT Medical for up to $800 million, which provides capital for organic investment and acquisitions, alongside major contracts for depleted uranium, enrichment initiatives, and reactor components like steam generators and fuel assemblies. Management reaffirmed 2026 guidance with specific targets for Government Operations revenue growth and outlined a framework for Commercial Operations following the divestiture of its medical business. The company maintains disciplined capital allocation, planning expenditures at 5% to 6% of revenue, while leveraging automation and digital tools to improve manufacturing throughput and support energy security needs.